Found: 8
Select item for more details and to access through your institution.
Targeting the LOX/ hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
- Published in:
- EMBO Molecular Medicine, 2015, v. 7, n. 8, p. 1063, doi. 10.15252/emmm.201404827
- By:
- Publication type:
- Article
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 1, p. 38, doi. 10.1038/s41416-023-02279-x
- By:
- Publication type:
- Article
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02937-0
- By:
- Publication type:
- Article
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection.
- Published in:
- Microsystems & Nanoengineering, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41378-021-00243-4
- By:
- Publication type:
- Article
Liquid Biopsy for Pancreatic Cancer Detection Using Infrared Spectroscopy.
- Published in:
- Cancers, 2022, v. 14, n. 13, p. N.PAG, doi. 10.3390/cancers14133048
- By:
- Publication type:
- Article
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article